共 158 条
[1]
Keating GM(2005)Posaconazole Drugs 65 1553-1567
[2]
Lien MY(2018)Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: a retrospective cohort study PLoS One 13 e0197851-367
[3]
Chou CH(2017)Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China J Infect Chemother 23 360-767
[4]
Lin CC(2015)Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China Tumour Biol 36 757-396
[5]
Xu XH(2010)Pharmacokinetic/pharmacodynamic profile of posaconazole Clin Pharmacokinet 49 379-745
[6]
Zhang L(2013)Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study Int J Clin Pharmacol Ther. 51 738-383
[7]
Cao XX(2018)Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: a retrospective study J Mycol Med. 28 379-243
[8]
Sun Y(2018)Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis Int J Hematol 107 235-222
[9]
Huang H(2004)Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults Br J Clin Pharmacol 57 218-966
[10]
Chen J(2009)Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers Antimicrob Agents Chemother 53 958-55